Charles River Laboratories International (NYSE:CRL) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.
Valuation & Earnings
This table compares Charles River Laboratories International and National Vision's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Charles River Laboratories International | $2.62 billion | 5.46 | $252.02 million | $6.73 | 42.71 |
National Vision | $1.72 billion | 2.25 | $32.80 million | $0.78 | 61.28 |
Charles River Laboratories International has higher revenue and earnings than National Vision. Charles River Laboratories International is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Charles River Laboratories International and National Vision's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Charles River Laboratories International | 10.68% | 22.41% | 7.66% |
National Vision | 0.32% | 4.97% | 1.84% |
Institutional & Insider Ownership
92.3% of Charles River Laboratories International shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 2.6% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Charles River Laboratories International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Charles River Laboratories International and National Vision, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Charles River Laboratories International | 0 | 4 | 12 | 0 | 2.75 |
National Vision | 0 | 2 | 7 | 0 | 2.78 |
Charles River Laboratories International currently has a consensus price target of $241.5625, indicating a potential downside of 15.97%. National Vision has a consensus price target of $43.25, indicating a potential downside of 9.52%. Given National Vision's stronger consensus rating and higher probable upside, analysts clearly believe National Vision is more favorable than Charles River Laboratories International.
Summary
Charles River Laboratories International beats National Vision on 9 of the 14 factors compared between the two stocks.